SUPERNUS PHARMACEUTICALS INC (SUPN)
US8684591089 - Common Stock
SUPN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. SUPN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. SUPN is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make SUPN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
SUPN had positive earnings in the past year.
In the past year SUPN had a positive cash flow from operations.
SUPN had positive earnings in each of the past 5 years.
In the past 5 years SUPN always reported a positive cash flow from operatings.
1.2 Ratios
SUPN has a Return On Assets of 4.45%. This is amongst the best in the industry. SUPN outperforms 86.46% of its industry peers.
Looking at the Return On Equity, with a value of 5.93%, SUPN belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
SUPN's Return On Invested Capital of 5.97% is amongst the best of the industry. SUPN outperforms 83.33% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 42.22%.
The 3 year average ROIC (3.33%) for SUPN is below the current ROIC(5.97%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.45% | ||
| ROE | 5.93% | ||
| ROIC | 5.97% |
ROA(3y)2.28%
ROA(5y)5%
ROE(3y)4.51%
ROE(5y)9.92%
ROIC(3y)3.33%
ROIC(5y)6.63%
1.3 Margins
SUPN's Profit Margin of 9.16% is amongst the best of the industry. SUPN outperforms 86.98% of its industry peers.
In the last couple of years the Profit Margin of SUPN has declined.
The Operating Margin of SUPN (12.19%) is better than 84.38% of its industry peers.
SUPN's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 89.04%, SUPN belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
SUPN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.19% | ||
| PM (TTM) | 9.16% | ||
| GM | 89.04% |
OM growth 3Y-58.75%
OM growth 5Y-41.33%
PM growth 3Y-79.29%
PM growth 5Y-61.95%
GM growth 3Y-1.39%
GM growth 5Y-2.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
The number of shares outstanding for SUPN has been increased compared to 1 year ago.
Compared to 5 years ago, SUPN has more shares outstanding
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SUPN has an Altman-Z score of 5.09. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
SUPN's Altman-Z score of 5.09 is fine compared to the rest of the industry. SUPN outperforms 79.69% of its industry peers.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.09 |
ROIC/WACC0.72
WACC8.32%
2.3 Liquidity
A Current Ratio of 2.20 indicates that SUPN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.20, SUPN is in line with its industry, outperforming 40.10% of the companies in the same industry.
SUPN has a Quick Ratio of 1.98. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
SUPN's Quick ratio of 1.98 is in line compared to the rest of the industry. SUPN outperforms 43.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.98 |
3. Growth
3.1 Past
SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 134.04%, which is quite impressive.
The Earnings Per Share has been decreasing by -7.43% on average over the past years.
The Revenue has been growing slightly by 6.78% in the past year.
SUPN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.24% yearly.
EPS 1Y (TTM)134.04%
EPS 3Y-15.98%
EPS 5Y-7.43%
EPS Q2Q%187.5%
Revenue 1Y (TTM)6.78%
Revenue growth 3Y5.3%
Revenue growth 5Y8.24%
Sales Q2Q%14.17%
3.2 Future
SUPN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.45% yearly.
SUPN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.91% yearly.
EPS Next Y90.16%
EPS Next 2Y17.45%
EPS Next 3Y19.35%
EPS Next 5Y28.45%
Revenue Next Year7.34%
Revenue Next 2Y1.87%
Revenue Next 3Y4.15%
Revenue Next 5Y6.91%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.28, SUPN is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 85.42% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.96, SUPN is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 18.55, the valuation of SUPN can be described as rather expensive.
SUPN's Price/Forward Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 80.21% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, SUPN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.28 | ||
| Fwd PE | 18.55 |
4.2 Price Multiples
91.67% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, SUPN is valued cheaply inside the industry as 90.10% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.5 | ||
| EV/EBITDA | 7.4 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SUPN has a very decent profitability rating, which may justify a higher PE ratio.
SUPN's earnings are expected to grow with 19.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y17.45%
EPS Next 3Y19.35%
5. Dividend
5.1 Amount
No dividends for SUPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SUPERNUS PHARMACEUTICALS INC
NASDAQ:SUPN (11/21/2024, 8:00:01 PM)
After market: 35.82 0 (0%)35.82
-0.3 (-0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.98B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.28 | ||
| Fwd PE | 18.55 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.18
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.45% | ||
| ROE | 5.93% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 12.19% | ||
| PM (TTM) | 9.16% | ||
| GM | 89.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.98 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)134.04%
EPS 3Y-15.98%
EPS 5Y
EPS Q2Q%
EPS Next Y90.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.78%
Revenue growth 3Y5.3%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y